Description: Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
Home Page: groupedevonian.com
360, rue des Entrepreneurs
Québec,
QC
G5V 4T1
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Ms. Colette Laurin C.A., CPA | Interim CFO, Corp. Sec. & Corp. Controller |
| Dr. Andre P. Boulet Ph.D. | Chief Scientific Officer |
| Mr. Pierre J. Montanaro | Pres, CEO & Director |
| Mr. Martin Moreau C.F.A., M.Sc. | VP of Fin. & Director |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.7491 |
| Price-to-Sales TTM: | 19.732 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |